Thousands of non-Muslims evacuated as violence flares in northwest Myanmar

Agencies
August 27, 2017

Yangon/Cox's Bazar, Aug 27: Myanmar's government said it has evacuated at least 4,000 non-Muslim villagers amid ongoing clashes in northwestern Rakhine state, as thousands more Rohingya Muslims sought to flee across the border to Bangladesh on Sunday.

The death toll from the violence that erupted on Friday with coordinated attacks by Rohingya insurgents has climbed to 98, including some 80 insurgents and 12 members of the security forces, the government said.

Fighting involving the military and hundreds of Rohingya across northwestern Rakhine continued on Saturday with the fiercest clashes taking place near the major town of Maungdaw, according to residents and the government.

Bracing for more violence, thousands of Rohingya - mostly women and children - were trying to forge the Naf river separating Myanmar and Bangladesh and the land border. Reuters reporters at the border could hear gunfire from the Myanmar side on Sunday.

Around 2,000 people have been able to cross into Bangladesh since Friday, according to estimates by Rohingya refugees living in the makeshift camps on the Bangladeshi side of the border.

The violence marked a dramatic escalation of a conflict that has simmered in the region since last October, when a similar but much smaller Rohingya attack prompted a brutal military operation beset by allegations of serious human rights abuses.

While the chaos and lack of access made detailed assessments difficult, experts said the latest attacks were so widespread they appeared to be more akin to a movement or an uprising, rather than a regular insurgent offensive.

One army source said the military was also struggling to differentiate.

"All the villagers become insurgents, what they're doing is like a revolution," said the source in Rakhine. "They don't care if they die or not. We can't tell who of them are insurgents."

CHALLENGE FOR SUU KYI

The treatment of approximately 1.1 million Muslim Rohingya in mainly Buddhist Myanmar has emerged as the biggest challenge for national leader Aung San Suu Kyi. Suu Kyi on Friday condemned the raids in which insurgents wielding guns, sticks and homemade bombs assaulted 30 police stations and an army base.

The Nobel Peace Prize laureate has been accused by some Western critics of not speaking out for the long-persecuted Muslim minority.

Win Myat Aye, Myanmar's minister for social welfare, relief and resettlement, told Reuters late on Saturday that 4,000 "ethnic villagers" who had fled their villages had been evacuated, referring to non-Muslim residents of the area.

The ministry is arranging facilities for them in places including Buddhist monasteries, government offices and local police stations in major cities.

"We are providing food to the people cooperating with the state government and local authorities," said Win Myat Aye. He was unable to describe the government's plans to help Rohingya civilians.

Rakhine residents in ethnically mixed or non-Muslim towns have readied knives and sticks to defend themselves. Many were stranded in their villages located in Muslim-majority areas as clashes continued and some roads had been mined, residents said.

People from Maungdaw and another town, Buthidaung, said on Sunday they worried food supply routes had been temporarily cut off.

"Buthidaung will face shortages of food, because no ships have arrived since the fighting started. It is also difficult to send food to the villagers stuck in other areas," Arakan National Party regional lawmaker, Tun Aung Thein, told Reuters by telephone from the town.

"BREAKING POINT"

The Myanmar army operation following attacks last year was heavily criticised internationally amid reports of civilian killings, rape and arson that a United Nations investigation said probably constituted crimes against humanity. Suu Kyi is blocking the U.N.-mandated probe into the allegations.

The Rohingya have for years endured apartheid-like conditions in northwestern Myanmar - they are denied citizenship and face severe restrictions on their movements. Many Myanmar Buddhists regard them as illegal immigrants from Bangladesh.

Observers worry that the latest attacks, across a wider area than October's violence and with many more people involved, represent a "breaking point" many Rohingya reached with the help of a charismatic insurgent leader, Ata Ullah.

Ata Ullah leads the Arakan Rohingya Salvation Army (ARSA) which instigated the October attacks and claimed responsibility for the latest offensive.

Myanmar declared ARSA, previously known as Harakah al-Yaqin, a terrorist organisation in the wake of the attacks.

Across the border, Bangladesh's foreign ministry said it was concerned thousands of "unarmed Myanmar nationals" were planning to enter the country.

Rohingya have been fleeing Myanmar to Bangladesh since the early 1990s and there are now around 400,000 in the country, where they are a source of tension between the two nations who both regard them as the other country's citizens.

The Myanmar army operation following attacks last year was heavily criticised internationally amid reports of civilian killings, rape and arson that a United Nations investigation said probably constituted crimes against humanity. Suu Kyi is blocking the U.N.-mandated probe into the allegations.

The Rohingya have for years endured apartheid-like conditions in northwestern Myanmar - they are denied citizenship and face severe restrictions on their movements. Many Myanmar Buddhists regard them as illegal immigrants from Bangladesh.

Observers worry that the latest attacks, across a wider area than October's violence and with many more people involved, represent a "breaking point" many Rohingya reached with the help of a charismatic insurgent leader, Ata Ullah.

Ata Ullah leads the Arakan Rohingya Salvation Army (ARSA) which instigated the October attacks and claimed responsibility for the latest offensive.

Myanmar declared ARSA, previously known as Harakah al-Yaqin, a terrorist organisation in the wake of the attacks.

Across the border, Bangladesh's foreign ministry said it was concerned thousands of "unarmed Myanmar nationals" were planning to enter the country.

Rohingya have been fleeing Myanmar to Bangladesh since the early 1990s and there are now around 400,000 in the country, where they are a source of tension between the two nations who both regard them as the other country's citizens.

Comments

mark sebastin
 - 
Sunday, 27 Aug 2017

line up everyone and shoot on their head . they are jihadists ....

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
August 1,2020

Mexico City, Aug 1: The number of people, who have died of COVID-19 in Mexico, has risen by 688 to 46,688 within the past 24 hours, Deputy Health Minister Hugo Lopez-Gatell said.

The number of victims in Mexico is now higher than in the United Kingdom, where 46,119 people have died of the disease. The largest number of fatalities - 153,311 - has been recorded in the United States, while Brazil comes second with 92,475 deaths.

Lopez-Gatell also said on late Friday that the number of confirmed coronavirus cases had increased by 8,458 to 424,637 over the past day.

A day earlier, the Latin American nation recorded 7,730 new cases of the coronavirus, with 639 fatalities.

The World Health Organisation (WHO) declared the COVID-19 outbreak a pandemic on March 11. To date, over 17.5 million people have been infected with the coronavirus worldwide, with over 677,000 fatalities, according to Johns Hopkins University.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 25,2020

Beijing, Mar 25: Around 5,000 people have signed up for the phase I clinical trial of recombinant novel coronavirus vaccine in Chinese city Wuhan where the virus first emerged late last year.

The recruitment for participants ended this week with nearly 5,000 volunteers signing up for the trial, state-run Beijing News reported on Wednesday.

A single-centre, open and dose-escalation phase I clinical trial for recombinant novel coronavirus vaccine (adenoviral vector) will be tested in healthy adults aged between 18 and 60 years, according to the ChiCTR (China Clinical Trial Register).

The trial, led by experts from the Academy of Military Medical Sciences, gained its approval on March 16 and the research is expected to last half a year.

Requiring at least 108 participants, the trial will be conducted in Wuhan, capital of Hubei province, the region worst-affected by the virus in the country, state-run China Daily reported.

Participants will experience 14-day quarantine restrictions after being vaccinated and their health condition will be recorded every day.

Chinese scientists are hastening the development of COVID-19 vaccines through five approaches --- inactivated vaccines, genetic engineering subunit vaccines, adenovirus vector vaccines, nucleic acid vaccines and vaccines using attenuated influenza virus as vectors.

So far, most teams are expected to complete preclinical research in April and some are moving forward faster, Wang Junzhi, an academician with the Chinese Academy of Engineering said.

Wang noted that research and development of COVID-19 vaccines in China is not slower than foreign counterparts and has been carried out in a scientific, standardised and orderly way.

China has stepped up the process to finalise vaccines to counter COVID-19 after Kaiser Permanente research facility in Seattle and Washington stole the march and began human trials.

China lifted tough restrictions on the Hubei province on Wednesday after a months-long lockdown as the country reported no new domestic cases.

But there were another 47 imported infections from overseas, the National Health Commission said. In total, 474 imported infections have been diagnosed in China -- mostly Chinese nationals returning home.

Comments

Y UDAYA CHANDAR
 - 
Monday, 13 Apr 2020

Dear Sir,

 

I am 77 but a very healthy person with remarkable immunity. I contracted Malaria fever in 1994 because of mosquito biting and I have not been sick anytime there after, not even for ordinary fever in the last 26 years.

 

I am sure you would like to conduct the trials on persons of varying criteria. I am sure you don't want to carry out the trials on perfectly healthy young individuals only. 

 

I am certain that  you want to try the vaccine on a 'common man' from 'general public.' I am ready for the trial and you can take me. I will be delighted. 

 

If you are not handling this matter kindly forward this mail to the correct agency.

 

I look forward to hearing from you.

 

Best regards.

 

If you are not moving forward, you are really moving backward.

Y Udaya Chandar

 

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.